Skip to content
Menu

Virax Biolabs Group Limited VRAX

Full chart Compare
Set alert

Price alert · VRAX

All alert types
0.33 USD -0.05 (-12.89%)

Regular-session close

0.37 +0.04 +11.48%

After hours · Nov 20, 4:00 PM ET

0.3287 Day range 0.3696
0.293 52-week range 21.75
YTD
-96.16%
1 year
-96.70%

5D -0.1764 (-28.38%)

0.40000.50000.60000.7000WedThuFriMonTue0.4451
Market cap
446.40K
Revenue (ttm)
156.42K
EPS (ttm)
-12.64
Shares out
4.34M
Forward P/E
-1.01
YTD return
-96.16%
1-year return
-96.70%
Volume
85.67K
Avg volume
361.14K
Open
0.3696
Previous close
0.381
Day's range
0.3287 – 0.3696
52-week range
0.293 – 21.75
Beta
1.93

Key statistics

50-day average
1.92
200-day average
1.66
Enterprise value
1.17M
Price / sales
53.30
Price / book
0.92
Revenue growth
2752.20%
Free cash flow
-4.99M
Total cash
3.67M
Total debt
224.30K
Return on equity
-95.98%
Short % of float
11.01%

Fundamental scorecard

8 of 25 checks passed on VRAX’s reported financials

ValueGrowthProfitabilityHealthDividend

8of 25 checks passed

  • Value 2 of 5
  • Growth 2 of 5
  • Profitability 1 of 5
  • Financial health 3 of 5
  • Dividend 0 of 5

Statements to Mar 31, 2026.

Financials — quick view

All financials
VRAX Revenue — annual 12.42K
VRAX Net income — annual -5.02M
VRAX EPS — annual -12.64

About Virax Biolabs Group Limited

Virax Biolabs Group Limited, a biotechnology company, distributes, markets, and sells diagnostics test kits for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company provides rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name. It also develops T-Cell IVD test kit for COVID-19, which intend to adapt for immunological profiling against multiple viral threats under the ViraxImmune Brand, as well as a proprietary mobile application for ViraxImmune that presents an individual's immunological profiling data and provide advice on the users' immune system. It serves clinics, pharmacies, laboratories, hospitals, and other groups, as well as corporations, pharmaceutical companies, research institutions, hospital systems, and public and private institutions. The company operates in Europe, South America, the Asia Pacific, Sub-Saharan Africa, and internationally. The company was formerly known as Virax Biolabs (Cayman) Limited and changed its name to Virax Biolabs Group Limited in September 2021. Virax Biolabs Group Limited was founded in 2013 and is headquartered in Lanarkshire, the United Kingdom.

Sector
Healthcare
Industry
Biotechnology
Country
United Kingdom

News

Your note

Sign in to keep a note on VRAX — it syncs with the Stock Master app.

Institution ownership

VRAX institution ownership
Holder% heldSharesValueReported
Renaissance Technologies, LLC4.50%145,400279.17KSep 29, 2024
Squarepoint Ops LLC1.26%40,62077.99KSep 29, 2024
UBS Group AG0.64%20,53039.42KSep 29, 2024
Jane Street Group, LLC0.36%11,63522.34KSep 29, 2024
Headlands Technologies LLC 0.01%185355Sep 29, 2024

Fund ownership

VRAX fund ownership
Holder% heldSharesValueReported
Fidelity NASDAQ Composite Index Fund0.02%5421.04KOct 30, 2024